Inhibition of NF-κB attenuates TRIM32-induced Bcl-2 upregulation and suggests its potential as a target to reduce resistance to cisplatin chemotherapy in NSCLC [40]. This evidence concerns the gene NFKB1 and non-small cell lung carcinoma.